Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Baxter reports solid Q3 performance amidst challenges and growth opportunities

Baxter International demonstrated resilience in Q3 2024 with sales growth and earnings exceeding expectations despite challenges.
The company's focus on operational efficiency, cost containment, and strategic divestitures positions it well for future growth.
Challenges from Hurricane Helene impact and Kidney Care separation are being addressed with a clear vision for sustained performance.
Opportunities for growth and margin expansion underscore Baxter's commitment to delivering value to shareholders and patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Baxter International has seen 7 consecutive years of dividend growth, but has not raised its dividend this year. The company's financials show slow revenue growth and a dramatic drop in earnings. Baxter's stock price has declined significantly over the past five years, making it a less attractive investment option compared to peers.

Dividend Challengers Review: Baxter International

NEW YORK , Aug. 14, 2023 /PRNewswire/ -- Attention Baxter International Inc. ("Baxter") (NYSE: BAX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 25, 2022 and February 8, 2023. If you suffered a loss on your investment in Baxter, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Baxter Investors of a Lead Plaintiff Deadline of September 11, 2023

NEW YORK , Aug. 12, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baxter International Inc. (NYSE: BAX) between May 12, 2022 and February 8, 2023, both dates inclusive (the "Class Period"), of the important September 11, 2023 lead plaintiff deadline. SO WHAT: If you purchased Baxter securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BAX

NEW YORK , Aug. 11, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Baxter International Inc. (NYSE: BAX). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/baxter-class-action-loss-submission-form/?id=43311&from=4 The lawsuit seeks to recover losses for shareholders who purchased Baxter between May 25, 2022 and February 8, 2023.

BAX SHAREHOLDER ALERT: Jakubowitz Law Reminds Baxter Shareholders of a Lead Plaintiff Deadline of September 11, 2023

NEW YORK , Aug. 5, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baxter International Inc. (NYSE: BAX) between May 12, 2022 and February 8, 2023, both dates inclusive (the "Class Period"), of the important September 11, 2023 lead plaintiff deadline. SO WHAT: If you purchased Baxter securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TOP RANKED LAW FIRM, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BAX

LOS ANGELES, CA / ACCESSWIRE / August 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE:BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 25, 2022 and February 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 11, 2023.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm

Medical device maker Baxter International has issued an urgent correction for certain software versions of its infusion pumps that deliver fluids into a patient's body, the U.S. drug regulator said on Monday.

Baxter issues urgent medical device correction for certain infusion pumps

NEW YORK , July 29, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baxter International Inc. (NYSE: BAX) between May 12, 2022 and February 8, 2023, both dates inclusive (the "Class Period"), of the important September 11, 2023 lead plaintiff deadline. SO WHAT: If you purchased Baxter securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BAX

NEW ORLEANS , July 28, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 11, 2023 to file lead plaintiff applications in a securities class action lawsuit against Baxter International Inc. (NYSE: BAX), if they purchased the Company's securities between May 12, 2022 and February 8, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.

BAXTER SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Baxter International Inc. - BAX

Baxter International Inc. (NYSE:BAX ) Q2 2023 Earnings Conference Call July 27, 2023 8:30 AM ET Company Participants Clare Trachtman - Vice President of Investor Relations Jose Almeida - Chairman, President & Chief Executive Officer Brian Stevens - Interim Chief Financial Officer & Chief Accounting Officer Conference Call Participants Robert Marcus - JPMorgan Larry Biegelsen - Wells Fargo Danielle Antalffy - SVB Securities Patrick Wood - Morgan Stanley Travis Steed - Bank of America Securities Vijay Kumar - Evercore ISI Matt Miksic - Barclays Operator Good morning, ladies and gentlemen, and welcome to Baxter International's Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded by Baxter and is copyrighted material.

Baxter International Inc. (BAX) Q2 2023 Earnings Call Transcript

LOS ANGELES, CA / ACCESSWIRE / July 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE:BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 25, 2022 and February 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 11, 2023.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm

Baxter's (BAX) second-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.

Baxter (BAX) Beats on Q2 Earnings, Revises 2023 EPS Guidance

Baxter International beat Wall Street expectations for second-quarter sales, helped by higher demand for its medical devices.

Baxter beats sales estimates on strong demand for medical devices

Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Baxter (BAX) Reports Q2 Earnings: What Key Metrics Have to Say

Baxter International (BAX) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.87 per share a year ago.

Baxter International (BAX) Lags Q2 Earnings and Revenue Estimates

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2023. “Baxter's second-quarter performance reflects ongoing solid demand for our diverse, durable portfolio of medically essential products,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “We are making progress across the transformational actions we announced at the start of 2023. These initiatives are focused on enhanc.

Baxter Reports Second-Quarter 2023 Results

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 11, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) securities between May 25, 2022 and February 8, 2023, inclusive (the “Class Period”). If you suffered a loss on your Baxter investments or would like to inquire about potentially pursu.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Baxter International Inc. (BAX)

LOS ANGELES, CA / ACCESSWIRE / July 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE:BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 25, 2022 and February 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 11, 2023.

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $BAX #BAX--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baxter International Inc. (NYSE: BAX) between May 12, 2022 and February 8, 2023, both dates inclusive (the “Class Period”), of the important September 11, 2023 lead plaintiff deadline. SO WHAT: If you purchased Baxter securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. W.

BAX INVESTOR NEWS: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BAX

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming September 11, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) securities between May 25, 2022 and February 8, 2023, inclusive (the “Class Period”). Investors suffering losses on their Baxter investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their le.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Baxter International Inc. (BAX)

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that Vantive will be the name of the company's proposed spinoff of its Renal Care and Acute Therapies businesses. Vantive is expected to launch as an independent, publicly traded company by July 2024 or earlier, subject to satisfaction of customary conditions. “Announcing the Vantive name is a critical milestone in our journey to becoming an independent company focused solely on ther.

Baxter Announces Vantive as the Name of Proposed Kidney Care Spinoff

LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE:BAX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 25, 2022 and February 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 11, 2023.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $500,000 to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $BAX #BAX--Baxter International, Inc. (BAX) Misled Investors Regarding the Impact of its Supply Chain Problems.

Baxter International, Inc. (BAX) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Baxter International, Inc. Securities Class Action

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) securities between May 25, 2022 and February 8, 2023, inclusive (the “Class Period”). Baxter investors have until September 11, 2023 to file a lead plaintiff motion. If you suffered a loss on your Baxte.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Baxter International Inc. (BAX) Investors

NEW YORK , July 24, 2023 /PRNewswire/ -- Bernstein Liebhard LLP: Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Baxter International, Inc. ("Baxter" or the "Company") (NYSE: BAX) between May 25, 2022 and February 8, 2023 , inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint").

BAXTER INTERNATIONAL, INC. (NYSE: BAX) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Baxter International, Inc.

News for Baxter Stock (BAX)